Tirzepatide generally delivers more weight loss than semaglutide , but both sit in a different league from older medications and lifestyleonly care
While not yet FDA-approved as a standalone agent, cagrilintide peptide therapy is being investigated for: Obesity treatment Metabolic syndrome management Adjunctive therapy for GLP-1 agonist non-responders Research in combination with emerging agents like retatrutide Note: As of 2025, cagrilintide is still considered a research compound in many jurisdictions
But there are key differences: Tirzepatide has the lowest nausea rate (31%), while Semaglutide (44%) and Retatrutide (43%) are similar
Even Skin Tone: It helps even out the skin tone by reducing redness, acne scars, and general skin discoloration
Holistic Wellness Approach Address inflammation, gut health, hormone balance, stress management, and metabolic functionnot just the number on the scale